Issue Date: September 18, 2017
Janssen drops hepatitis C treatment
Johnson & Johnson’s Janssen division says it will halt development of the hepatitis C treatment JNJ-4178, citing rising numbers of existing therapies. JNJ-4178 is a cocktail of three small-molecule antivirals: AL-335, obtained when Janssen acquired Alios BioPharma for $1.75 billion; simeprevir, licensed from Medivir; and odalasvir from Achillion Pharmaceuticals. Share prices at Medivir and Achillion fell by double digits after the news. Janssen says it will shift emphasis toward hepatitis B therapies.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society